Onychomycosis Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Blueberry Therapeutics, Hallux, Pfizer, Moberg Pharma AB, Polichem S.A, Nitric BioThera

Posted on
by

Onychomycosis Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Blueberry Therapeutics, Hallux, Pfizer, Moberg Pharma AB, Polichem S.A, Nitric BioThera
DelveInsight’s “Onychomycosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the Onychomycosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Onychomycosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the Onychomycosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Onychomycosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Onychomycosis Market Forecast

 

Some of the key facts of the Onychomycosis Market Report: 

  • The Onychomycosis market size in the United States was valued USD 1,757 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • By aggregating the instances in the various nations, the total prevalence cases in the 7MM were determined. The estimated number of onychomycosis cases worldwide (7MMprevalent cases) in 2022 was close to 85,435,000, with the majority of cases being found in the US
  • Germany had the largest market among the European nations in 2022, with about USD 275 million, followed by France with more than USD 218 million
  • More than 13,390,000 cases of onychomycosis were diagnosed in total in the EU4 and UK markets in 2022, and this number is anticipated to climb during the projection period (2023–2022)
  • According to analysts, there were roughly 4,000,000 mild cases, about 6,000,000 moderate cases, and about 5,000,000 severe cases of onychomycosis in the United States
  • In Japan, there were more than 12,763,000 prevalent cases overall in 2022
  • Key Onychomycosis Companies: Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Moberg Pharma AB, Polichem S.A, Nitric BioTherapeutics, Inc, MediQuest Therapeutics, Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A, Bausch Health Americas, Inc., NanoBio Corporation, Merck Sharp & Dohme LLC, Dow Pharmaceuticals, Janssen Korea, Ltd., Dong-A ST Co., Ltd., and others
  • Key Onychomycosis Therapies: MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Terbinafine HCl, Organogel, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, Efinaconazole, NB-002, HTS-519 Insert, SCH 56592, IDP-108, Itraconazole, Jublia®, and others
  • The Onychomycosis epidemiology based on gender analyzed that Onychomycosis is more common in females than males, in the United States
  • The Onychomycosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Onychomycosis pipeline products will significantly revolutionize the Onychomycosis market dynamics.

 

Onychomycosis Overview

The most prevalent nail infection in the world, onychomycosis is a fungal infection that thickens and discolors the nail plate. However, recent studies have shown that mixed infections including those caused by non dermatophyte moulds (NDMs) are more common than previously believed, especially in warmer areas. Dermatophytes were once assumed to be the primary cause of onychomycosis.

 

Get a Free sample for the Onychomycosis Market Report 

https://www.delveinsight.com/report-store/onychomycosis-market

 

Onychomycosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Onychomycosis Epidemiology Segmentation:

The Onychomycosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Onychomycosis
  • Prevalent Cases of Onychomycosis by severity
  • Gender-specific Prevalence of Onychomycosis
  • Diagnosed Cases of Episodic and Chronic Onychomycosis

 

Download the report to understand which factors are driving Onychomycosis epidemiology trends @ Onychomycosis Epidemiology Forecast

 

Onychomycosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Onychomycosis market or expected to get launched during the study period. The analysis covers Onychomycosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Onychomycosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Onychomycosis Therapies and Key Companies

  • MOB-015: Moberg Pharma
  • BB2603: Blueberry Therapeutics
  • HSG: Hallux
  • Tavaborole: Pfizer
  • MOB015B: Moberg Pharma AB
  • P-3058: Polichem S.A
  • Terbinafine HCl: Nitric BioTherapeutics, Inc
  • Organogel: MediQuest Therapeutics
  • TDT067 and Lamisil: Celtic Pharma
  • Albaconazole: GlaxoSmithKline
  • HTU-520: Hisamitsu Pharma
  • P-3058: Polichem S.A
  • Efinaconazole: Bausch Health Americas, Inc.
  • NB-002: NanoBio Corporation
  • HTS-519 Insert: Hallux, Inc.
  • SCH 56592: Merck Sharp & Dohme LLC
  • IDP-108: Dow Pharmaceuticals
  • Itraconazole: Janssen Korea, Ltd.,
  • Jublia®: Dong-A ST Co., Ltd.

 

Discover more about therapies set to grab major Onychomycosis market share @ Onychomycosis Treatment Market

 

Onychomycosis Market Strengths

  • The introduction of novel, inexpensive, and non-invasive diagnostic technologies have led to rapid and accurate diagnosis of onychomycosis, hence increased the rate of diagnosis

 

Onychomycosis Market Opportunities

  • Current treatments have poor adherence and tolerability creating an opportunity for the key players to work on these areas

 

Scope of the Onychomycosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Onychomycosis Companies: Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Moberg Pharma AB, Polichem S.A, Nitric BioTherapeutics, Inc, MediQuest Therapeutics, Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A, Bausch Health Americas, Inc., NanoBio Corporation, Merck Sharp & Dohme LLC, Dow Pharmaceuticals, Janssen Korea, Ltd., Dong-A ST Co., Ltd., and others
  • Key Onychomycosis Therapies: MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Terbinafine HCl, Organogel, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, Efinaconazole, NB-002, HTS-519 Insert, SCH 56592, IDP-108, Itraconazole, Jublia®, and others
  • Onychomycosis Therapeutic Assessment: Onychomycosis current marketed and Onychomycosis emerging therapies
  • Onychomycosis Market Dynamics: Onychomycosis market drivers and Onychomycosis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Onychomycosis Unmet Needs, KOL’s views, Analyst’s views, Onychomycosis Market Access and Reimbursement 

 

To know more about Onychomycosis companies working in the treatment market, visit @ Onychomycosis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Onychomycosis Market Report Introduction

2. Executive Summary for Onychomycosis

3. SWOT analysis of Onychomycosis

4. Onychomycosis Patient Share (%) Overview at a Glance

5. Onychomycosis Market Overview at a Glance

6. Onychomycosis Disease Background and Overview

7. Onychomycosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Onychomycosis 

9. Onychomycosis Current Treatment and Medical Practices

10. Onychomycosis Unmet Needs

11. Onychomycosis Emerging Therapies

12. Onychomycosis Market Outlook

13. Country-Wise Onychomycosis Market Analysis (2019–2032)

14. Onychomycosis Market Access and Reimbursement of Therapies

15. Onychomycosis Market Drivers

16. Onychomycosis Market Barriers

17.  Onychomycosis Appendix

18. Onychomycosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services